溶瘤病毒，如已获批用于治疗黑色素瘤和恶性胶质瘤的 IMLYGIC 和 DELYTACT，正在被各大公司研究用于新的癌症治疗方法，其中包括 Genelux 的 Oncolytic viruses, like IMLYGIC and DELYTACT approved for melanoma and malignant glioma, are being researched by major companies for new cancer treatments, including Genelux'
溶瘤病毒、RNA 或 DNA 是一种很有前景的癌症治疗方法，它可以靶向并摧毁癌细胞，同时刺激免疫系统。 Oncolytic viruses, RNA or DNA, are promising cancer treatments, targeting and destroying cancer cells while stimulating the immune system. FDA 批准的疗法 IMLYGIC 和 DELYTACT 分别针对黑色素瘤和恶性胶质瘤。 FDA-approved therapies IMLYGIC and DELYTACT target melanoma and malignant glioma, respectively. Replimune、Genelux 和 Imugene 等主要公司正在研究新的溶瘤病毒治疗方法，其中 Genelux 的 Olvi-Vec 正处于治疗铂耐药性卵巢癌的 III 期研究，而 Replimune 的 RP1 正在开发中。 Major companies like Replimune, Genelux, and Imugene are researching new oncolytic virus treatments, with Genelux's Olvi-Vec in Phase III for platinum-resistant ovarian cancer and Replimune's RP1 in development.